Back to top

Oruka: Differentiated IL-23 Profile and Solid Cash Runway Support Maintained Buy Rating and Unchanged $125 Price Target

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Oruka Therapeutics today and set a price target of $125.00. Sam Slutsky has given hi...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Oruka Therapeutics, Inc. (ORKA)